最新ニュース Poolbeg Pharma (OTC:POLBF) 株価情報

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma PLC

Macro Economic Events

Macro Notification

News

Econ #s

Economics

General

US Nonfarm Payrolls (Dec) 256K vs 164K Est.

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares are trading higher premarket after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42908301/delta-air-lines-announces-december-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">fourth-quarter 2024 results</a>.
Delta reported fourth-quarter adj. operating revenue growth of 5.7% year-over-year to $14.437 billion. GAAP operating revenue was $15.56 billion (+9.4% YoY), beating the consensus of $14.212 billion.
Adjusted average fuel price was $2.34 per gallon, down from $3.00 from last year&#8217;s quarter. Adjusted EPS was $1.85 (+44.5% YoY), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of $1.76.</a>
Related: <a target="_blank" href="https://www.benzinga.com/general/travel/25/01/42899701/delta-q4-earnings-preview-can-bullish-trends-keep-the-stock-flying-high" rel="noreferrer noopener">Delta Q4 Earnings Preview: Can Bullish Trends Keep The Stock Flying High?</a>
Total passenger revenue for the quarter grew 5% year over year to $12.815 billion; cargo revenue grew 32% year over year to $249 million, and Other revenue was $2.495 billion (+34% year over year).
Delta recorded an adjusted operating income of $1.735 billion, up from $1.33 billion YoY, with an adjusted operating margin of 12%, up ~230 bps.
Adjusted operating expenses increased by 3% YoY to $12.702 billion, and Adjusted Non-fuel costs were $9.9 billion for the quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42901060/delta-expands-premium-travel-experience-with-uber-youtube-and-joby-partnerships-unveiled-at-ces-2025" rel="noreferrer noopener">Delta Expands Premium Travel Experience with Uber, YouTube, and Joby Partnerships</a>
Delta generated an adjusted operating cash flow of $1.8 billion in the December quarter. Full-year adjusted operating cash flow reached $8.0 billion, with gross capital expenditures of $4.8 billion, resulting in $3.4 billion free cash flow for 2024.
Adjusted net debt at the December quarter-end decreased to $18 billion, a reduction of $3.6 billion from the end of 2023. Liquidity stood at $6.1 billion at year-end, including $3.1 billion in undrawn revolver capacity.
The passenger load factor was flat at 84%. DAL&#8217;s Air Traffic Liability ended the quarter at $7.1 billion.
&#8220;As we move into 2025, we expect strong demand for travel to continue, with consumers increasingly seeking the premium products and experiences that Delta provides. Our differentiated strategy and best-in-class operations, combined with demand strength and an increasingly constructive industry backdrop, position us to deliver the best financial year in Delta&#8217;s 100-year history, with pre-tax income greater than $6 billion, earnings per share greater than $7.35 and free cash flow of more than $4 billion,&#8221; commented Ed Bastian, Delta&#8217;s chief executive officer.
&#8220;As efficiency gains continue, we expect non-fuel unit cost growth to continue in the low-single digits for the full year 2025 as efficiencies offset the impact of slower capacity growth and continued investments in our people and the customer experience,&#8221; stated Dan Janki, Delta&#8217;s chief financial officer.
First Quarter 2025 Outlook (Non-GAAP): DAL&#8217;s total revenue is expected to grow 7% &#8211; 9% year-over-year with an operating margin of 6% &#8211; 8%. Earnings per share are forecasted between $0.70 and $1.00 versus the $0.77 estimate.
2025 Outlook: The company&#8217;s EPS is projected at greater than $7.35, reflecting 10%+ YoY growth and 19%+ on a non-GAAP basis.
Price Action: DAL shares are trading higher by 7.78% at $66.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42908495/us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data" target="_blank" rel="noreferrer noopener">US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday&#8217;s Crucial Jobs Data</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Large Cap

Guidance

Movers

Delta Takes Flight As Q4 Earnings Beat Expectations, Fueled By Premium Travel Demand And Efficiency Gains

ACM Research's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NYSE">ACMR</a>) short percent of float has risen 9.83% since its last report. The company recently reported that it has 4.31 million shares sold short, which is 9.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ACM Research Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ACM Research has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ACM Research's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ACM Research's peer group average for short interest as a percentage of float is 4.72%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

ACMR

Peering Into ACM Research's Recent Short Interest

US Nonfarm Payrolls (Dec) 223K vs 164K Est.; Prior 182K

Intuitive Machines's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NYSE">LUNR</a>) short percent of float has fallen 4.79% since its last report. The company recently reported that it has 14.22 million shares sold short, which is 17.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Machines Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Machines has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Intuitive Machines's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Machines's peer group average for short interest as a percentage of float is 6.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LUNR

Looking Into Intuitive Machines's Recent Short Interest

Stride's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) short percent of float has risen 10.31% since its last report. The company recently reported that it has 5.99 million shares sold short, which is 19.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Stride Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Stride has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Stride's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stride's peer group average for short interest as a percentage of float is 2.77%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Stride's Recent Short Interest

Mike Wilson, Morgan Stanley's chief investment officer, has some advice for anyone looking to advance in their career: Take risks. Be bold. And don't fear being wrong.
"You've got to be willing to take a stand on stuff," Wilson told Business Insider. "Whether it's in a meeting, with people you report to or pointing out things you don't agree with, kind of making a firm stance."
But here's the kicker: Wilson believes real success comes from doing what most people won't – betting against the crowd.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
</ul>
<h2 class="wp-block-heading">Why Contrarian Views Pay Off</h2>
Wilson says taking "personal risk" is where you can find real rewards, especially on Wall Street. The real money is made with "contrarian views," he explained. But it's not always easy and involves "accepting the idea that you're going to be wrong along the way," he said. "Ultimately, how you deal with those consequences will determine whether you're successful or not."
In short: Play it safe and you'll miss the big wins.
<h2 class="wp-block-heading">Betting On Yourself</h2>
Wilson isn't just throwing out motivational sound bites. He's talking about taking risks that others shy away from. For him, being wrong occasionally is just part of the process.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The key is to stick to your convictions, even if it feels uncomfortable. "On Wall Street, personal risk often means taking contrarian views," he added.
That advice doesn't just apply to Wall Street, though. It's a mindset anyone can use to advance their career or investments.
<h2 class="wp-block-heading">Learn From The Best</h2>
Wilson isn't the only one offering top-tier advice. Wall Street heavyweights like David Kostin of Goldman Sachs, BlackRock's Rick Rieder and Bloomberg's Anna Wong have also contributed.
Kostin's advice? Show up. "I can't imagine how a young person is going to actually absorb all the dimensionality of what's happening … and not be in the office," he said.
Rieder, meanwhile, suggests focusing on the future. "The world's changing faster than anybody really recognizes," he explained.
And Wong encourages curiosity: "Constantly being curious, even if there might not be an obvious payoff to it."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">The Takeaway</h2>
Wilson's advice is to Take a chance, go against the grain, be prepared to fail and not let that stop you.
For those willing to embrace risk, the personal and financial rewards could be worth it. As Wilson put it, personal risk often means being a contrarian.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

Morgan Stanley's Mike Wilson On Taking Risks – 'The Real Money Is Made With Contrarian Views'

USA Unemployment Rate For December 4.1% Vs 4.2% Est.; 4.2% Prior

Diana Shipping Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with SwissMarine Pte. Ltd., Singapore, for one of its Capesize dry bulk vessels, the m/v New York. The gross charter rate is US$6,300 per day for the first trip of the charter period and US$17,600 per day for the balance period of the time charter, in each case minus a 5.00% commission paid to third parties, for a period until minimum January 15, 2026 up to maximum March 30, 2026. The charter is expected to commence on January 12, 2025.
The "New York" is a 177,773 dwt Capesize dry bulk vessel built in 2010.
The employment of "New York" is anticipated to generate approximately US$6.03 million of gross revenue for the minimum scheduled period of the time charter.

Contracts

Diana Shipping Inc. Announces Time Charter Contract For m/v New York With SwissMarine; The Gross Charter Rate Is $6,300 Per Day For The First Trip Of The Charter Period And $17,600 Per Day For The Balance Period Of The Time Charter; Anticipated To Generate ~$6.03M Of Gross Revenue For The Minimum Scheduled Period Of The Time Charter

Rail Vision Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>) (the "Company"), a technology company at the forefront of revolutionizing railway safety and the data-related market, has received a purchase order for its MainLine product from one of the leading Central America freight operators. This purchase order will support a proof of concept (POC) aimed at demonstrating the MainLine's advanced capabilities in enhancing rail safety and operational efficiency.
The freight operator operates a vast fleet of locomotives across extensive rail networks. Known for its commitment to safety and technological modernization, the freight operator has invested significantly in upgrading its infrastructure, implementing efficient scheduling systems and adopting advanced safety protocols to minimize accidents and environmental risks.
Rail Vision's MainLine product was selected for its ability to provide real-time object detection and classification using state-of-the-art artificial intelligence (AI) and long-range vision sensors. These capabilities align with the freight operator's stringent safety standards and strategic goal of leveraging cutting-edge technology to optimize operations.
This purchase adds to Rail Vision's proven track record with leading freight operators and Class 1 rail operators in the Americas, where its rail safety technologies have already been demonstrated and deployed.

RVSN

Rail Vision Announces Purchase Order For MainLine Product From Leading Central America Freight Operator For Proof Of Concept; Product Features AI And Long-Range Sensors For Enhanced Rail Safety And Efficiency; No Financial Terms Disclosed

OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the rapid expansion of its Specialty Bracing (OPSB) division with entrance into 3 target markets within Indiana, Colorado, and Florida.&nbsp;
Each of these new locations broadens the Company's position in targeted geographies to partner with pediatric orthopedic surgeons in the region to treat children with non-operative solutions. The OPSB division, launched in early 2024, has a multi-year strategy to increase access to care around the world by way of opening new (‘greenfield') clinics and strategically acquiring clinics in target geographies.&nbsp;
The new&nbsp;Indianapolis, Indiana based OPSB&nbsp;clinic is located near Riley Children's Hospital satellite facility and close to Peyton Manning Children's Hospital. This greenfield site is the first OPSB clinic in the state, exclusively focused on pediatric and adolescent patients.&nbsp;

Biotech

KIDS

OrthoPediatrics Corp. Announces Expansion Of Its Specialty Bracing Division With Entrance Into 3 Target Markets Within Indiana, Colorado, And Florida.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

BTCS

BTCS Launches Its Staker Protection Plan To Enhance Financial Stability for Ethereum Validators with Revenue Shield Increasing Profits by Up to 4%, Integrated Full Block Pre-Confirmations, Compliance Framework, and Advanced Order Flow Integration.

On January&nbsp;8, 2025, Climb Bio, Inc. (the "Company") entered into a technology transfer and exclusive license agreement (the "Agreement") with Beijing Mabworks Biotech Co., Ltd. ("Mabworks"), pursuant to which Mabworks granted to the Company (1)&nbsp;an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the "Licensed Intellectual Property") to develop, manufacture and commercialize Mabworks' proprietary antibodies associated with Mabworks' proprietary antibody program identified as MIL116 (the "Licensed Compounds" or "CLYM116") and products containing the Licensed Compounds ("Licensed Products") outside of China, Hong Kong, Macau, and Taiwan (the "Licensed Territory"), (2) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in China, Hong Kong, Macau, and Taiwan (the "China Territory") and (3)&nbsp;a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the China Territory in connection with certain global clinical studies (as described below).
Under the terms of the Agreement, the Company is obligated to pay to Mabworks a $9.0&nbsp;million upfront payment, a total of up to $30.0&nbsp;million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $832&nbsp;million upon the achievement of certain commercial milestones for all Licensed Products. In addition, the Company is obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory.

CLYM

Climb Bio Entered Technology Transfer And Exclusive License Agreement With Beijing Mabworks Biotech Co.; Climb Obligated To Pay Mabworks $9M Upfront And Up To $30M On Milestones, With Total Up To $832M Upon Achievement Of Certain Milestones For All Licensed Products

Netcapital Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>, NPCLW))), a digital private capital markets ecosystem, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 270,861 shares of common stock of the Company originally issued in December 2023 and May 2024, having an exercise price of $10.85 per share, at a reduced exercise price of $1.80 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282590). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $487,549, prior to deducting placement agent fees and estimated offering expenses.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A-5 warrants to purchase up to 361,148 shares of common stock and new unregistered Series A-6 warrants to purchase up to 180,574 shares of common stock. The Series A-5 new warrants will have an exercise price of $2.07 per share, will be exercisable six months after issuance, and will expire five years thereafter. The Series A-6 new warrants will have an exercise price of $2.07 per share, will be exercisable six months after issuance and will expire eighteen months thereafter.
The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general working capital purposes.

Offerings

NCPL

Netcapital Announces Definitive Agreements for Exercise of 270,861 Warrants at Reduced Price of $1.80/Share, Anticipates Gross Proceeds of $487,549

<ul>
<li>Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million</li>
<li>Placement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024</li>
<li>Lantheus shareholding in Radiopharm increases to 12.16% following the placement</li>
<li>The funds raised will be applied to the development of Radiopharm's clinical pipeline</li>
</ul>
SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has executed a subscription agreement for a private placement of ordinary shares to Lantheus Holdings Inc. ( "Lantheus"), raising US$5.0 million (A$8.0 million).
The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur within 7 days.
The placement replaces 6-month options that the Company issued in August 2024 (see ASX announcement 20 June 2024).

LNTH

RADX

Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M

FORR

Forrester Research Announced 6% Workforce Reduction, Expects Pre-Tax Expenses $5.2M-$5.6M

Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) will release earnings for its fourth quarter, before the <a href="https://www.benzinga.com/quote/BAC/earnings">opening bell on Thursday, Jan. 16.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at 77 cents per share. That&#8217;s up from 35 cents per share in the year-ago period. According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Bank of America projects quarterly revenue of $25.09 billion, compared to $21.96 billion a year earlier.
On Jan. 7, UBS analyst Erika Najarian upgraded Bank of America from Neutral to Buy and announced a $53 price target.
With the recent buzz around Bank of America, some investors may be eyeing potential gains from the company's dividends too. Bank of America currently offers an annual dividend yield of 2.25%, or a quarterly dividend of 26 cents per share ($1.04 a year).
To figure out how to earn $500 monthly from Bank of America, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Bank of America's $1.04 dividend: $6,000 / $1.04 = 5,769 shares.
So, an investor would need to own approximately $266,585 worth of Bank of America, or 5,769 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.04 = 1,154 shares, or $53,326 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
BAC Price Action: Shares of Bank of America gained by 0.3% to close at $46.21 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>
Image: Shutterstock

Long Ideas

How To Earn $500 A Month From Bank of America Stock Ahead Of Q4 Earnings

Findings show significant brain activity after a single 20mg dose of SP-624 in healthy subjects
Phase 2b/3 study of SP-624 in major depressive disorder is underway
SP-624 has the potential to be the first treatment specifically for females with Major Depression
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arrivobio.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Arrivo+BioVentures&amp;index=1&amp;md5=b26643e71e80d6b6dbb548fa286adb84">Arrivo BioVentures</a> today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies.
Arrivo's SP-624-103 study is a double blind, placebo-controlled study with three cohorts. Cohort 1 is comprised of 12 healthy subjects (8 active, 4 placebo) who received 20mg of SP-624 over a 15-day dosing period. Assessments, including quantitative EEG (qEEG) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffireflyneuro.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Firefly+Neuroscience%26%238217%3Bs&amp;index=2&amp;md5=faf584bd97e07c7f189d793410dbf3cb">Firefly Neuroscience's</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FAIFF%2F&amp;,%20esheet=54176223&amp;,%20newsitemid=20250110201020&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+AIFF&amp;,%20index=3&amp;,%20NASDAQ:%3Ca%20class=">AIFF</a>) brain network analytics (BNA&#x2122;), were performed at Day One and Day 15 pre- and post-dose. Cohort 2 is actively enrolling 12 patients diagnosed with major depressive disorder (MDD). The subject composition of the 3rd cohort will be determined after the completion of the second cohort.
Cohort 1 results of the SP-624-103 study include:
<ul>
<li>Subjects showed an increase in beta power, particularly in the frontal-central regions compared to patients taking placebo after a single dose, suggesting enhanced synaptic plasticity and neuronal connectivity.</li>
<li>Subjects showed a decrease in delta power. This is important as increases in delta activity are often associated with reduced cortical arousal and depressive states.</li>
<li>Evoked potential response findings suggest enhanced neural efficiency in early perceptual processing and improved decision-making speed and context updating.</li>
</ul>

AIFF

Arrivo BioVentures Announces Brain Activity Increase With Single 20mg SP-624 Dose In Healthy Subjects; Phase 2b/3 Trial For Major Depression In Progress; Potential First Treatment For Females With Major Depression; Enhanced Synaptic Plasticity And Neuronal Connectivity Observed

Management

ROLR

High Roller Technologies Appoints Kristofer Muscat As Chief Operating Officer

<ul>
<li>The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma &nbsp;</li>
<li>Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients &nbsp;</li>
<li>Seven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple Negative Breast Cancer ("TNBC"), and several patients have been treated</li>
</ul>
SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4335946-1&amp;h=1845873411&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a>&nbsp;("Intensity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.&nbsp;

INTS

Intensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients

Poolbeg Pharma announces board role change and launch of EIP

Poolbeg Pharma announces cash balance of £12.2M as at 31 Dec 2023

Poolbeg Pharma to voluntarily delist from OTCQB market

POLBF

Legal

Press Releases

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

Poolbeg Pharma PLC Announces Appointment of Joint Broker

Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023

Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

Comments

Poolbeg Pharma

ニュース

最新ニュース Poolbeg Pharma (OTC:POLBF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル